Severe corneal changes following intravitreal injection of bevacizumab.
OBJECTIVE
To report a series of severe corneal changes following intravitreal injection of bevacizumab (Avastin) for age-related macular degeneration.


METHODS
Retrospective noncomparative case series.


METHODS
The authors retrospectively reviewed the corneal changes that developed after the procedure in 1200 (460 patients) intravitreal injections of bevacizumab.


RESULTS
Five significant corneal changes (1.1%) occurred in these patients within the 1st postinjection week. The severe corneal changes included corneal infiltrative keratitis (n = 2) and corneal stromal edema and descemet folds (n = 3). The findings depended on clinical examination and biomicroscopic and confocal evaluation. In terms of causality assessment, no rechallenge was possible. The appropriate treatment was applied and recovery was achieved in all patients during the follow-up period.


CONCLUSIONS
Intravitreal injection of bevacizumab may cause corneal changes. The safety and effects of bevacizumab on the cornea should be evaluated in detail.
Bayar
Sezin Akca
SA
Department of Ophthalmology, Baskent University Hospital, Fevzi Cakmak cad. 10. Sokak, 06490 Bahcelievler, Ankara, Turkey. sezinakca@gmail.com
Altinors
Dilek D
DD
Kucukerdonmez
Cem
C
Akova
Yonca A
YA
D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D001372:Aza Compounds / Q000627:therapeutic use; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy*; D015715:Corneal Edema / Q000175:diagnosis* / Q000188:drug therapy / Q000276:immunology; D003886:Descemet Membrane / Q000276:immunology / Q000473:pathology; D003907:Dexamethasone / Q000627:therapeutic use; D005260:Female; D024841:Fluoroquinolones; D006801:Humans; D007634:Keratitis / Q000175:diagnosis* / Q000188:drug therapy / Q000276:immunology; D008268:Macular Degeneration / Q000188:drug therapy*; D008297:Male; D000077266:Moxifloxacin; D011239:Prednisolone / Q000627:therapeutic use; D011804:Quinolines / Q000627:therapeutic use; D012189:Retrospective Studies; D014792:Visual Acuity / Q000187:drug effects
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D000068258:Bevacizumab; D003907:Dexamethasone; D011239:Prednisolone; D000077266:Moxifloxacin